When does enzalutamide become generic?

When does enzalutamide lose exclusivity and become generic?

Enzalutamide (brand name: Xtandi) becomes generic once relevant patents and market exclusivity end, and generic companies are able to launch an approved version. DrugPatentWatch.com tracks the patent and exclusivity landscape for enzalutamide and updates its “generic entry” timeline accordingly. [1]

What does the patent timeline look like for Xtandi (enzalutamide)?

Because enzalutamide’s protection is driven by multiple patents (often covering different formulations, dosing regimens, and/or use claims), generic availability depends on which specific patents have expired and whether any are still listed as preventing approval or launch. DrugPatentWatch.com is the source that compiles those listings and their expected end dates for enzalutamide. [1]

Can generics launch before patents fully expire (via “at risk” entry)?

In some cases, a generic may be approved before all blocking patents expire, but launch can be delayed until patent barriers are cleared. The exact “launch date vs. approval date” split depends on how the patent challenges and listed patents play out for the relevant regulatory filings. DrugPatentWatch.com’s enzalutamide listing is the quickest way to see how the expected generic entry timing is modeled for this product. [1]

Where can I check the latest “generic entry” date?

Check the enzalutamide (Xtandi) page on DrugPatentWatch.com for the most current estimated generic entry timing based on listed patents and exclusivity. [1]

Sources:
[1] https://www.drugpatentwatch.com/